


Volatility meter



GLOBAL EQUITY

Code 8507 / GLEQ2

Manulife Templeton Global Equity Fund (Registered Plans Only)

How the underlying fund is invested

Composition



Equity Industry



Geographic split



Top holdings within the underlying fund

(As at September 30, 2018)

Teva Pharmaceutical Industries Ltd DR	2.14%
Oracle Corp	2.10%
Citigroup Inc	1.95%
BP PLC	1.89%
Royal Dutch Shell Plc B	1.89%
Seven & i Holdings Co Ltd	1.88%
Samsung Electronics Co Ltd	1.85%
Allergan plc	1.71%
Standard Chartered PLC	1.66%
Sanofi SA	1.59%

Primary investment process

Fundamental, Bottom-up

Equity style and capitalization

Value	Core/Blend	Growth	
			Large
			Medium
			Small
●			All cap

All rates of return are shown before investment management fees or taxes have been deducted.
This fund invests primarily outside of North America.
Source: Lipper, a Thomson Reuters company

UNDERLYING FUND -> Templeton Global Equity Trust - Series Institutional

Objective The Templeton Global Equity Fund is managed to achieve long-term capital appreciation by investing in a diversified portfolio of equity securities of companies around the world, excluding Canada.

Managed by Franklin Templeton Investments Corp

Fund managers Franklin Templeton Investments Corp.

Inception date

Underlying fund

January 1992

Segregated Fund

November 1996

Total assets

\$1,036.2 million

\$404.4 million


Operating expense (2017)

-

0.20%

Overall past performance

This graph shows how a \$10,000 investment in this fund would have changed in value over time, based on gross returns. **Gross rates of return are shown before investment management fees have been deducted.**



Annualized compound returns (As at September 30, 2018)

This table shows the historical annual compound total return of the fund compared with the benchmark, as outlined in the rate of return expectation below.

	3 mo (%)	1 year (%)	2 year (%)	3 year (%)	5 year (%)	10 year (%)
Fund	1.26	7.89	11.21	8.67	11.33	9.88
Benchmark	3.32	16.01	14.52	12.88	15.06	11.37

Investment objective

The Fund is expected to outperform the MSCI World Index (\$ Cdn).